

# Paolo Paganetti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8089212/publications.pdf>

Version: 2024-02-01

77  
papers

15,478  
citations

81743

39  
h-index

66788

78  
g-index

87  
all docs

87  
docs citations

87  
times ranked

27482  
citing authors

#	ARTICLE	IF	CITATIONS
1	The heat shock response, determined by QuantiGene multiplex, is impaired in HD mouse models and not caused by HSF1 reduction. <i>Scientific Reports</i> , 2021, 11, 9117.	1.6	7
2	Tau Seeds in Extracellular Vesicles Induce Tau Accumulation in Degradative Organelles of Cells. <i>DNA and Cell Biology</i> , 2021, 40, 1185-1199.	0.9	3
3	Emerging Evidences for an Implication of the Neurodegeneration-Associated Protein TAU in Cancer. <i>Brain Sciences</i> , 2020, 10, 862.	1.1	28
4	Tau affects P53 function and cell fate during the DNA damage response. <i>Communications Biology</i> , 2020, 3, 245.	2.0	36
5	Hijacking Endocytosis and Autophagy in Extracellular Vesicle Communication: Where the Inside Meets the Outside. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 595515.	1.8	22
6	Chloroquine, the Coronavirus Crisis, and Neurodegeneration: A Perspective. <i>Frontiers in Neurology</i> , 2020, 11, 596528.	1.1	2
7	Protoporphyrin IX tracer fluorescence modulation for improved brain tumor cell lines visualization. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2019, 201, 111640.	1.7	15
8	Phosphorylation of nuclear Tau is modulated by distinct cellular pathways. <i>Scientific Reports</i> , 2018, 8, 17702.	1.6	31
9	<sc>ER</sc> -associated degradation of proteasome-resistant <sc>ATZ</sc> polymers occurs via receptor-mediated vesicular transport. <i>EMBO Journal</i> , 2018, 37, .	3.5	144
10	Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence. <i>Journal of Neuro-Oncology</i> , 2017, 133, 497-507.	1.4	18
11	HSF1-dependent and -independent regulation of the mammalian in vivo heat shock response and its impairment in Huntington's disease mouse models. <i>Scientific Reports</i> , 2017, 7, 12556.	1.6	27
12	Split GFP technologies to structurally characterize and quantify functional biomolecular interactions of FTD-related proteins. <i>Scientific Reports</i> , 2017, 7, 14013.	1.6	31
13	Motifs in the tau protein that control binding to microtubules and aggregation determine pathological effects. <i>Scientific Reports</i> , 2017, 7, 13556.	1.6	35
14	Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. <i>Nature Communications</i> , 2017, 8, 45.	5.8	242
15	LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2016, 5, 347-355.	0.9	27
16	Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats. <i>Experimental Neurology</i> , 2016, 280, 80-88.	2.0	20
17	Synthesis and structure-activity relationship of 2,6-disubstituted pyridine derivatives as inhibitors of $\beta$ -amyloid-42 aggregation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 3330-3335.	1.0	14
18	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701

#	ARTICLE	IF	CITATIONS
19	BACE-1 is expressed in the blood-brain barrier endothelium and is upregulated in a murine model of Alzheimer's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 1281-1294.	2.4	53
20	Deciphering the role of tau in neurodegeneration using Adeno-Associated Viral (AAV) vectors to express human tau in the mouse forebrain. <i>Molecular Neurodegeneration</i> , 2013, 8, .	4.4	0
21	Human genome-guided identification of memory-modulating drugs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4369-74.	3.3	20
22	Transgenic expression of $\tau$ 1 antibody in brain neurons impairs age-dependent amyloid deposition in APP23 mice. <i>Neurobiology of Aging</i> , 2013, 34, 2866-2878.	1.5	4
23	Atg4b-Dependent Autophagic Flux Alleviates Huntington's Disease Progression. <i>PLoS ONE</i> , 2013, 8, e68357.	1.1	30
24	Increased Efflux of Amyloid- $\beta$ Peptides through the Blood-Brain Barrier by Muscarinic Acetylcholine Receptor Inhibition Reduces Pathological Phenotypes in Mouse Models of Brain Amyloidosis. <i>Journal of Alzheimer's Disease</i> , 2013, 38, 767-786.	1.2	11
25	Discovery and Structure Activity Relationship of Small Molecule Inhibitors of Toxic $\beta$ -Amyloid-42 Fibril Formation. <i>Journal of Biological Chemistry</i> , 2012, 287, 34786-34800.	1.6	53
26	Suppression of protein aggregation by chaperone modification of high molecular weight complexes. <i>Brain</i> , 2012, 135, 1180-1196.	3.7	103
27	Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse. <i>Behavioural Brain Research</i> , 2012, 229, 308-319.	1.2	11
28	A Screen for Enhancers of Clearance Identifies Huntingtin as a Heat Shock Protein 90 (Hsp90) Client Protein. <i>Journal of Biological Chemistry</i> , 2012, 287, 1406-1414.	1.6	84
29	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	4.3	3,122
30	TR-FRET-Based Duplex Immunoassay Reveals an Inverse Correlation of Soluble and Aggregated Mutant huntingtin in Huntington's Disease. <i>Chemistry and Biology</i> , 2012, 19, 264-275.	6.2	70
31	Hdac6 Knock-Out Increases Tubulin Acetylation but Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease. <i>PLoS ONE</i> , 2011, 6, e20696.	1.1	91
32	Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model. <i>Journal of Neurochemistry</i> , 2011, 119, 398-407.	2.1	85
33	Microtiter plate quantification of mutant and wild-type huntingtin normalized to cell count. <i>Analytical Biochemistry</i> , 2011, 410, 304-306.	1.1	14
34	Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. <i>Journal of Clinical Investigation</i> , 2011, 121, 3306-3319.	3.9	151
35	Perturbation with Intrabodies Reveals That Calpain Cleavage Is Required for Degradation of Huntingtin Exon 1. <i>PLoS ONE</i> , 2011, 6, e16676.	1.1	27
36	Macrocyclic BACE-1 inhibitors acutely reduce A $\beta$ in brain after po application. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 603-607.	1.0	55

#	ARTICLE	IF	CITATIONS
37	The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease. <i>Molecular Neurodegeneration</i> , 2010, 5, 26.	4.4	86
38	Huntingtin cleavage product A forms in neurons and is reduced by gamma-secretase inhibitors. <i>Molecular Neurodegeneration</i> , 2010, 5, 58.	4.4	16
39	$\beta$ -Secretase cleavage is not required for generation of the intracellular C-terminal domain of the amyloid precursor family of proteins. <i>FEBS Journal</i> , 2010, 277, 1503-1518.	2.2	22
40	Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. <i>Human Molecular Genetics</i> , 2010, 19, 1528-1538.	1.4	100
41	Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease. <i>Human Molecular Genetics</i> , 2010, 19, 65-78.	1.4	185
42	Proteolysis of Mutant Huntingtin Produces an Exon 1 Fragment That Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington Disease. <i>Journal of Biological Chemistry</i> , 2010, 285, 8808-8823.	1.6	259
43	Rapid Cerebral Amyloid Binding by $A\beta$ Antibodies Infused into $\beta$ -Amyloid Precursor Protein Transgenic Mice. <i>Biological Psychiatry</i> , 2010, 68, 971-974.	0.7	14
44	Optimization of an HTRF Assay for the Detection of Soluble Mutant Huntingtin in Human Buffy Coats: A Potential Biomarker in Blood for Huntington Disease. <i>PLOS Currents</i> , 2010, 2, RRN1205.	1.4	24
45	Development of a Method for the High-Throughput Quantification of Cellular Proteins. <i>ChemBioChem</i> , 2009, 10, 1678-1688.	1.3	21
46	Inducible mutant huntingtin expression in HN10 cells reproduces Huntington's disease-like neuronal dysfunction. <i>Molecular Neurodegeneration</i> , 2009, 4, 11.	4.4	29
47	Structure-based design and synthesis of macrocyclic peptidomimetic $\beta$ -secretase (BACE-1) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1361-1365.	1.0	35
48	Macrocyclic peptidomimetic $\beta$ -secretase (BACE-1) inhibitors with activity in vivo. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1366-1370.	1.0	54
49	Single-step detection of mutant huntingtin in animal and human tissues: A bioassay for Huntington's disease. <i>Analytical Biochemistry</i> , 2009, 395, 8-15.	1.1	115
50	Acetylation Targets Mutant Huntingtin to Autophagosomes for Degradation. <i>Cell</i> , 2009, 137, 60-72.	13.5	367
51	Splicing of intron 3 of human BACE requires the flanking introns 2 and 4. <i>Biochemical and Biophysical Research Communications</i> , 2009, 388, 434-438.	1.0	2
52	Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. <i>Journal of Neurochemistry</i> , 2008, 104, 846-858.	2.1	103
53	Consequences of Individual N-glycan Deletions and of Proteasomal Inhibition on Secretion of Active BACE. <i>Molecular Biology of the Cell</i> , 2008, 19, 4086-4098.	0.9	25
54	BACE1 and Mutated Presenilin-1 Differently Modulate $A\beta$ 40 and $A\beta$ 42 Levels and Cerebral Amyloidosis in APPDutch Transgenic Mice. <i>Neurodegenerative Diseases</i> , 2007, 4, 127-135.	0.8	19

#	ARTICLE	IF	CITATIONS
55	Exogenous Induction of Cerebral $\beta$ -Amyloidogenesis Is Governed by Agent and Host. <i>Science</i> , 2006, 313, 1781-1784.	6.0	875
56	EDEM1 regulates ER-associated degradation by accelerating de-mannosylation of folding-defective polypeptides and by inhibiting their covalent aggregation. <i>Biochemical and Biophysical Research Communications</i> , 2006, 349, 1278-1284.	1.0	154
57	Detection of a Soluble Form of BACE-1 in Human Cerebrospinal Fluid by a Sensitive Activity Assay. <i>Clinical Chemistry</i> , 2006, 52, 1168-1174.	1.5	66
58	$\beta$ -site specific intrabodies to decrease and prevent generation of Alzheimer's $A\beta$ peptide. <i>Journal of Cell Biology</i> , 2005, 168, 863-868.	2.3	98
59	Structure-Based Design, Synthesis, and Memapsin 2 (BACE) Inhibitory Activity of Carbocyclic and Heterocyclic Peptidomimetics. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 5175-5190.	2.9	74
60	EDEM Contributes to Maintenance of Protein Folding Efficiency and Secretory Capacity. <i>Journal of Biological Chemistry</i> , 2004, 279, 44600-44605.	1.6	40
61	Yeast growth selection system for the identification of cell-active inhibitors of $\beta$ -secretase. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2004, 1674, 29-39.	1.1	20
62	BACE ( $\beta$ -secretase) modulates the processing of APLP2 in vivo. <i>Molecular and Cellular Neurosciences</i> , 2004, 25, 642-649.	1.0	107
63	Role of EDEM in the Release of Misfolded Glycoproteins from the Calnexin Cycle. <i>Science</i> , 2003, 299, 1397-1400.	6.0	431
64	Targeting Presenilin-type Aspartic Protease Signal Peptide Peptidase with $\beta$ -Secretase Inhibitors. <i>Journal of Biological Chemistry</i> , 2003, 278, 16528-16533.	1.6	114
65	Sequential assistance of molecular chaperones and transient formation of covalent complexes during protein degradation from the ER. <i>Journal of Cell Biology</i> , 2002, 158, 247-257.	2.3	204
66	Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. <i>Journal of Neurochemistry</i> , 2002, 80, 799-806.	2.1	116
67	The disulphide bonds in the catalytic domain of BACE are critical but not essential for amyloid precursor protein processing activity. <i>Journal of Neurochemistry</i> , 2002, 80, 1079-1088.	2.1	31
68	A Splice Variant of $\beta$ -Secretase Deficient in the Amyloidogenic Processing of the Amyloid Precursor Protein. <i>Journal of Biological Chemistry</i> , 2001, 276, 12019-12023.	1.6	74
69	Amyloid $\beta$ interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. <i>Nature Neuroscience</i> , 2000, 3, 460-464.	7.1	252
70	Membrane-type 1 Matrix Metalloprotease (MT1-MMP) Enables Invasive Migration of Glioma Cells in Central Nervous System White Matter. <i>Journal of Cell Biology</i> , 1999, 144, 373-384.	2.3	232
71	Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 13287-13292.	3.3	1,355
72	Distinct Processing of Endogenous and Overexpressed Recombinant Presenilin 1. <i>Neurobiology of Aging</i> , 1997, 18, 181-189.	1.5	18

#	ARTICLE	IF	CITATIONS
73	Effect of alkalizing agents on the processing of the $\beta^2$ -amyloid precursor protein. Brain Research, 1996, 716, 91-100.	1.1	77
74	The Carboxyl Termini of $\beta^2$ -Amyloid Peptides 1-40 and 1-42 Are Generated by Distinct $\beta^3$ -Secretase Activities. Journal of Biological Chemistry, 1996, 271, 28655-28659.	1.6	151
75	Intracellular Accumulation of $\beta^2$ -Amyloid in Cells Expressing the Swedish Mutant Amyloid Precursor Protein. Journal of Biological Chemistry, 1995, 270, 26727-26730.	1.6	88
76	Proteolytic processing of the Aplysia A peptide precursor in AtT-20 cells. Brain Research, 1994, 633, 53-62.	1.1	13
77	Heterogeneous distribution of calmodulin-and cAMP-dependent regulation of $Ca^{2+}$ uptake in cardiac sarcoplasmic reticulum subfractons. FEBS Journal, 1988, 176, 535-541.	0.2	15